Paddock Recalls Moexipril HCl Tablets Due to Dissolution Failure
Paddock Laboratories is recalling one lot of Moexipril HCl Tablets 7.5mg due to a dissolution failure found during routine stability testing.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a temporary or medically reversible adverse health consequence. The hazard is a quality defect (dissolution failure) without reported injuries or illnesses, fitting the Moderate severity criteria for low-risk contamination or quality issues.
Plain-English summary
Paddock Laboratories, LLC is recalling one lot of Moexipril HCl Tablets 7.5mg. The affected lot number is 2012028142, with an expiration date of 1/2014. The recall involves 2,267 bottles of the prescription medication.
The recall was initiated because of a non-conformity dissolution failure result identified during routine stability testing at the 6-month test interval. This defect indicates that the tablets may not dissolve properly in the body, which could affect the medication's performance.
The product was distributed nationwide. Consumers and healthcare providers should check their inventory for this specific lot number and expiration date. If found, the medication should be returned to the pharmacy or point of purchase for a refund or replacement.
The recalled product
- Product
- Moexipril HCl Tablets 7.5mg, 100 tabs, Rx Only, Paddock Laboratories, Inc., Minneapolis, MN 55427, NDC 0574-0110-01 ,
- Manufacturer
- Paddock Laboratories, LLC
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 2,267
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 2012028142 exp. 1/2014
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Paddock Laboratories, LLC
See all →- ModeratePaddock Recalls Evamist Estradiol Spray Due to Vial Cracks
FDA (Drugs) · 2018-04-04
- ModeratePerrigo Recalls Clindamycin Oral Solution Due to Particulate Matter
FDA (Drugs) · 2014-03-26
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paroxetine Hydrochloride Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateAjanta Pharma Recalls Ranolazine Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
Similar recalls
- ModerateUCB Recalls Univasc Tablets Due to Failed Dissolution Testing
FDA (Drugs) · 2015-08-26
- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- LowLiothyronine Sodium Tablets Recalled for Failed Stability Testing
FDA (Drugs) · 2013-05-15
- ModerateApotex Recalls Aripiprazole Tablets Due to Dissolution Failures
FDA (Drugs) · 2020-11-25
- ModerateApotex Recalls Paroxetine Hydrochloride Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateMayne Pharma Recalls Liothyronine Sodium Tablets for Dissolution Failures
FDA (Drugs) · 2017-12-06